摘要
内分泌治疗是激素受体阳性乳腺癌的主要治疗手段,贯穿于早期和复发转移乳腺癌治疗的全过程。新型内分泌药物和细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂等靶向药物的研发,改善了激素受体阳性乳腺癌患者的预后,改变了治疗格局。然而,临床研究数据的更新,提供更多治疗选择的同时,也产生了新的临床问题。我们结合国内外临床研究数据和实践经验,经讨论后达成本共识,旨在规范内分泌治疗在激素受体阳性乳腺癌新辅助治疗、辅助治疗和复发转移解救治疗中的应用。
Endocrine therapy is the primary systemic therapy for hormone receptor-positive breast cancer,which runs through the whole process of treatment for early and metastatic breast cancer.The development of new endocrine agents and targeted drugs such as cyclin-dependent kinases 4/6(CDK4/6)inhibitors has improved outcome of patients with hormone receptor-positive breast cancer and changed the treatment landscape.The update of clinical research data provides more treatment options,calling for treatment optimization.Experts had a deep discussion around the hot topics on endocrine therapy of breast cancer,and formulated the'Expert consensus on endocrine therapy of breast cancer(2023 edition)'.This consensus is based on research data worldwide and clinical practice experience,with the aims of standardizing clinical diagnosis and optimizing treatment in neoadjuvant,adjuvant and metastatic setting of hormone receptor-positive breast cancer.
作者
张少华
王晓稼
江泽飞
代表乳腺癌内分泌治疗共识专家组
Zhang Shaohua;Wang Xiaojia;Jiang Zefei;Represetative consensus expert panel on endocrime therapy of breast cancer(Senior Department of Oncology,the Fifth Medical Centre of Chinese People′s Liberation Army(PLA)General Hospital,Beijing 100071,China;Breast Medical Oncology,Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Hangzhou 310022,China;不详)
出处
《中华医学杂志》
CAS
CSCD
北大核心
2023年第38期2993-3001,共9页
National Medical Journal of China
基金
北京医学奖励基金会(YXJL-2020-0941-0751)
关键词
乳腺肿瘤
内分泌治疗
专家共识
Breast neoplasms
Endocrine therapy
Expert consensus
作者简介
通信作者:江泽飞,Email:jiangzefei@csco.org.cn
